ASH 2019 Annual Meeting Highlights in MDS

Activity of Venetoclax-Based Therapy in MDS – Jorge E. Cortes, MD Run Time: 07:08 Begin

Ongoing Phase 1b of First-in-Class Anti CD47 Antibody Magrolimab in Combination with Azacitidine – Guillermo Garcia-Manero, MD Run Time: 05:36 Begin

Combination Treatment with Lenalidomide-Epoetin Alfa in Low-risk Non-del(5q) MDS: Final Results of the E2905 Intergroup Phase 3 Study – Alan F. List, MD Run Time: 03:25 Begin

Assessment of Longer-Term Efficacy and Safety in the Phase 3 MEDALIST Trial – Alan F. List, MD Run Time: 04:51 Begin

Oral Rigosertib Combined with Azacitidine as First-Line Therapy in Patients with Higher-Risk MDS: Report of a Phase 2 Study – Shyamala C. Navada, MD, MSCR Run Time: 05:35 Begin

Phase 2/3 Study of Oral Rigosertib and Injectable Azacitidine versus Injectable Azacitidine in Treatment-Naïve Patients with Higher-Risk MDS – Shyamala C. Navada, MD, MSCR Run Time: 06:23 Begin

Phase 2 Study of Enasidenib in Patients with High-Risk IDH2-Mutated MDS: Preliminary Results – Eytan M. Stein, MD Run Time: 03:47 Begin